|
|
Volumn 95, Issue 14, 2003, Pages 1030-1031
|
|
Prostate cancer prevention trial yields positive results, but with a few cautions
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
FINASTERIDE;
PLACEBO;
PROSTATE SPECIFIC ANTIGEN;
ANDROSTANOLONE;
ANTIANDROGEN;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
ENZYME INHIBITOR;
TESTOSTERONE;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
CANCER GRADING;
CANCER MORTALITY;
CANCER PREVENTION;
CANCER STATISTICS;
CARCINOGENESIS;
CLINICAL TRIAL;
HUMAN;
MALE;
NOTE;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATE HYPERTROPHY;
RISK BENEFIT ANALYSIS;
TREATMENT OUTCOME;
URINARY TRACT OBSTRUCTION;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
CHEMOPROPHYLAXIS;
CONTROLLED CLINICAL TRIAL;
HOSPITALIZATION;
INCIDENCE;
METABOLISM;
METHODOLOGY;
MIDDLE AGED;
MULTICENTER STUDY;
PATHOLOGY;
PROSTATE TUMOR;
RANDOMIZED CONTROLLED TRIAL;
AGED;
ANDROGEN ANTAGONISTS;
ANTINEOPLASTIC AGENTS, HORMONAL;
CHEMOPREVENTION;
DIHYDROTESTOSTERONE;
ENZYME INHIBITORS;
FINASTERIDE;
HUMANS;
INCIDENCE;
MALE;
MIDDLE AGED;
MULTICENTER STUDIES;
PROSTATIC NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
SEVERITY OF ILLNESS INDEX;
TESTOSTERONE;
|
|
EID: 0043268828
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/95.14.1030 Document Type: Note |
|
Times cited : (13)
|
|
References (0)
|